Study of VRN101099 for HER2-positive solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, VRN101099, for people with HER2-positive or HER2-mutated cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older (19 in Korea).
- Your cancer must be HER2-positive or have a HER2 mutation, as shown by a prior lab test.
- You must have at least one tumor that can be measured or seen on a scan.
- Standard cancer treatments are no longer helping you, or none are available.
- You must be well enough to carry out daily activities (ECOG score 0 or 1).
- You must agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral targeted therapy (VRN110755) for people with EGFR-mutant lung cancer. It is for those whose cancer has advanced or spread, and who either have not been treated yet or who stopped responding to previous EGFR pills.
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
This trial tests a new drug, SKB103, for people with HER2-negative breast cancer that has not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
This Phase 1 study tests ZV0203, a new investigational treatment, in people with HER2-positive advanced or metastatic solid tumors that cannot be removed and have not responded to standard treatment. The goal is to find a safe dose and see how the disease responds.
This trial tests a new drug, CAN016, for people with advanced solid tumors that have HER2 expression or a HER2 gene change. You may qualify if your cancer has gotten worse after trying other HER2-targeted treatments.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
Hear when a new HER2-positive Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.